Russian Federation
Moskva, Russian Federation
Russian Federation
Main idea of this article is to make a short overview of modern MALT lymphoma treatment approaches. Historically, surgery was the leading treatment modality. Discovery of H.pylori involvement, invention of new drugs and chemotherapy protocols, wide use of monoclonal antibodies, significantly raised the effectiveness of conservative treatment. Routine use of CT scanning, invention of conformal, precise radiotherapy techniques allowed to achieve fine radiotherapy treatment results, especially in the case of combined chemo – radiotherapy protocols. That is why nowadays conservative treatment plays more significant role. However, complete remission cannot be achieved in all the cases. More research is required and thorough analyze of advantages and disadvantages of every technique and their combinations.
primary non-hodgkin gastric lymphoma, extranodal
1. Nered S.N., Shaaenkov V.A., Poddubnaya I.V. Khirurgicheskoe i konservativnoe lechenie oslozh-nennykh form nekhodzhkinskikh limfom zheludka. Onkologiya. Zhurnal im.P.A. Gertsena. 2012. №1. C. 28-32.
2. Poddubnaya I.V. Ekstranodal´nye NKhL. Klinicheskaya gematologiya Pod red. M.A.Volkovoy. M.: Meditsina, 2001. C. 336-375.
3. Aviles A., Nambo M.J., Neri N. The role of surgery in primary gastric lymphoma: results of a con-trolled clinical trial. Ann Surg. 2004. V. 240. P. 44-50.
4. Fischbach W., Goebeler-Kolve M.E., Dragosics B. Long term outcome of patients with gastric mar-ginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication: experience from a large prospective series. Gut. 2004. V.53.P. 34-37.
5. Harris NL., Jaffe ES., Diebold Y. World Health Organization classifiacation of neoplastic diseases of the hematoetic and lymphoid tissues. Report of the Clinical Advisory Commettee Meeting - Asirlie House, Vir-ginia, November 1997. J. Clin. Oncol. 1999. V.17. P. 3835-3849.
6. Jager G., Neumeister P., Brezinschek R. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002. V. 20, №18. R. 3872-3877.
7. Jager G., Neumeister P., Quehenberger F. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol. 2006. V.17, №11. R.1722-1723.
8. Koch P., del Valle F., Berdel W.E. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the pros-pective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001. V.19. P. 3874-3883.
9. Levy M., Copie-Bergman C., Cameiro C. Prognostic value of translocation t(11;18) in tumoral re-sponse of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005. V. 23. P. 5061-5066.
10. Liu H., Ye H., Ruskone-Fourmestraux A. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002. V.122. P. 1286-1294.
11. Martinelli G., Laszlo D., Ferreri A. Clinical activity of rituximab in gastric marginal zone non-hodgkin’s lymphoma resistant to or not eligible for anti-helicobacter pylori therapy. J Clin Oncol. 2005. V. 20, 9. R. 1979-1983.
12. Raderer M., Jager G., Brugger S. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003. V.65, №4. P.306-310.
13. Ruskoneґ-Fourmestraux A., Lavergne A., Aegerter P.H. Predictive factors for regression of gastric MALT lymphoma after anti- Helicobacter pylori treatment. Gut. 2001. V. 48. P.297-303.
14. Sam S.Yoon, Daniel G.Colit, Carol S. Portlock. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg. 2004. V. 240. P. 28-37.
15. Vrieling C., de Jong D., Boot H. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008. V. 87 P. 405-411.
16. Wohrer S., Drach J., Hejna M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003. V.14, №12. P. 1758-1761.
17. Wohrer S., Puspok Ayu, Drach J. Rituximab, cyclophosphamide, doxorubicin, vincristine and pred-nisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004. V.1, №15. P.1086-1090.
18. Wundisch T., Dieckhoff P., Gunther A. 10-Year follow-up of 120 patients with gastric MALT lym-phoma after Helicobacter pylori eradication - histological residual disease and second cancers. J Clin Oncol. 2008. V. 34. P. 2061-2070.
19. Wundisch T., Thiede C., Morgner A. Long-term follow-up of gastric MALT lymphoma after Helico-bacter pylori eradication. J Clin Oncol. 2005. V.23, №31. P.1-7.
